This led to a clinical trial using intramuscular mouse-derived NGF injections for ALS treatment, involving 28 days of daily injections followed by 6 months without treatment, with the goal of providing neuroprotection and promoting the survival of motor neurons. This evidence concerns the gene NGF and amyotrophic lateral sclerosis.